Evidence map›Paper›PMID 41291192›Full record

ReviewCommunications medicine2025

Addressing infectious diseases in Africa by accelerating drug discovery through data science.

Gemma Turon, Jason Hlozek, Miquel Duran-Frigola, Kelly Chibale, John G Woodland

Abstract readReview
In one paragraph

Review in Communications medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Gemma TuronErsilia Open Source Initiative, Barcelona, Spain.ORCID http://orcid.org/0000-0001-6798-0275
Jason HlozekDepartment of Chemistry and Holistic Drug Discovery and Development (H3D) Centre, University of Cape Town, Cape Town, South Africa.ORCID http://orcid.org/0000-0002-8675-6954
Miquel Duran-FrigolaErsilia Open Source Initiative, Barcelona, Spain.
Kelly ChibaleDepartment of Chemistry and Holistic Drug Discovery and Development (H3D) Centre, University of Cape Town, Cape Town, South Africa. kelly.chibale@uct.ac.za.ORCID http://orcid.org/0000-0002-1327-4727
John G WoodlandDepartment of Chemistry and Holistic Drug Discovery and Development (H3D) Centre, University of Cape Town, Cape Town, South Africa. john.woodland@uct.ac.za.ORCID http://orcid.org/0000-0001-6273-5596

Funding

Wellcome Trust
6 · The paper itself

Abstract

Despite being rich in natural resources and scientific talent, Africa continues to bear a staggering infectious disease burden. Historically, health innovation on the continent has relied on international funding and has been constrained by limited infrastructure and the emigration of skilled professionals. Data science tools offer a promising alternative, typically requiring fewer costly resources than traditional empirical research, with the potential to empower African scientists to generate tangible and impactful health solutions for the continent. Rapid progress in data science is expected to transform infectious disease research; thus, it is encouraging that numerous African initiatives are already applying data science tools to tackling pressing unmet medical needs, particularly in drug discovery. These efforts include identifying novel therapeutic targets, predicting drug-like molecules and their synthesis, enhancing clinical trial success rates and preparing for future disease threats. This review examines the current landscape of data science in infectious disease drug discovery across Africa.

Identifiers

PMID41291192
PMCPMC12647589

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.